Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;11(8 Pt 1):865-878.
doi: 10.1016/j.jchf.2023.04.014. Epub 2023 May 31.

Late Right Heart Failure After Left Ventricular Assist Device Implantation: Contemporary Insights and Future Perspectives

Affiliations
Free article
Review

Late Right Heart Failure After Left Ventricular Assist Device Implantation: Contemporary Insights and Future Perspectives

Indranee Rajapreyar et al. JACC Heart Fail. 2023 Aug.
Free article

Erratum in

  • Correction.
    [No authors listed] [No authors listed] JACC Heart Fail. 2023 Aug;11(8 Pt 1):1035. doi: 10.1016/j.jchf.2023.06.007. JACC Heart Fail. 2023. PMID: 37558384 No abstract available.

Abstract

Late right heart failure (RHF) is increasingly recognized in patients with long-term left ventricular assist device (LVAD) support and is associated with decreased survival and increased incidence of adverse events such as gastrointestinal bleeding and stroke. Progression of right ventricular (RV) dysfunction to clinical syndrome of late RHF in patients supported with LVAD is dependent on the severity of pre-existing RV dysfunction, persistent or worsening left- or right-sided valvular heart disease, pulmonary hypertension, inadequate or excessive left ventricular unloading, and/or progression of the underlying cardiac disease. RHF likely represents a continuum of risk with early presentation and progression to late RHF. However, de novo RHF develops in a subset of patients leading to increased diuretic requirement, arrhythmias, renal and hepatic dysfunction, and heart failure hospitalizations. The distinction between isolated late RHF and RHF due to left-sided contributions is lacking in registry studies and should be the focus of future registry data collection. Potential management strategies include optimization of RV preload and afterload, neurohormonal blockade, LVAD speed optimization, and treatment of concomitant valvular disease. In this review, the authors discuss definition, pathophysiology, prevention, and management of late RHF.

Keywords: late right heart failure; left ventricular assist device; mitral regurgitation; pulmonary hypertension; tricuspid regurgitation.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Tedford has consulting relationships with Medtronic, Abbott, Aria CV Inc, Alleviant, Acceleron, Cytokinetics, Itamar, Edwards Lifesciences, Eidos Therapeutics, Lexicon Pharmaceuticals, Gradient, and United Therapeutics; is on a steering committee for Acceleron/Merck and Abbott; is on a research advisory board for Abiomed; and performs hemodynamic core lab work for Merck. Dr Wieselthaler is a consultant for Medtronic. Dr Rame is a consultant for Actelion Pharmaceuticals and Abbott; was a steering committee member for the SOPRANO study; and was a coinvestigator for the RESTAGE trial. Dr Caliskan is a scientific advisory board member for FineHeart. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Similar articles

Cited by

Publication types

LinkOut - more resources